EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.118 | (4-amidinohenyl)methanesulfonyl 1-fluoride |
61% inhibition at 1 mM |
   |
| 3.4.21.118 | 1-(2-bromobenzene-1-sulfonyl)-5-methyl-3-(2-methyl-4,5-dihydro-1H-imidazol-4-yl)-1H-indole |
compound is a promising lead for development of novel kallikrein-8 inhibitors. It binds stably to the kallikrein-8 S1 binding site |
|
| 3.4.21.118 | 1-(3,5-difluorophenyl)-5-hydroxy-7-(4-hydroxy-3,5-dimethoxyphenyl)-6,7-dihydro-1H-pyrrolo[3,2-b] pyridine-3-carboxylic acid |
i.e. ZINC61720639 |
|
| 3.4.21.118 | 2-[[5-(2-chlorophenyl)-4-imino-3-methyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl]sulfanyl]-N-(2,5-dimethoxyphenyl)acetamide |
- |
|
| 3.4.21.118 | 4,4'-[pentane-1,5-diylbis(oxy)]bis(3,5-dibromobenzenecarboximidamide) |
- |
|
| 3.4.21.118 | 4-amino-N3-[(2R)-1-(tert-butylamino)-1-oxopropan-2-yl]-N3-(3-chloro-4-fluorophenyl)-2H-pyrrole-3,5-dicarboxamide |
- |
|
| 3.4.21.118 | alpha2-antiplasmin |
- |
|
| 3.4.21.118 | antipain |
95% inhibition at 0.1 mM |
|
| 3.4.21.118 | antipain |
50% inhibition at 0.00046 mM |
|
| 3.4.21.118 | antipain |
0.2 mM, 100% inhibition |
|
